Nucor earnings beat by $0.08, revenue fell short of estimates
In a turbulent market environment, Clorox Co (NYSE:CLX) stock has touched a 52-week low, dipping to $125.66. The household and professional products manufacturer, known for its namesake bleach and cleaning supplies, has faced significant headwinds over the past year, reflected in a -5.65% change in its stock price. Despite market challenges, the company maintains its position as a dividend aristocrat, having raised dividends for 48 consecutive years, with a current yield of 3.83%. Investors have shown concern as the company grapples with various challenges, including supply chain disruptions and changing consumer behavior post-pandemic. The 52-week low marks a notable moment for Clorox, as the company continues to navigate through a complex economic landscape while striving to regain its footing and deliver value to shareholders. According to InvestingPro analysis, the stock appears undervalued at current levels, with 7 analysts recently revising their earnings expectations upward. For deeper insights and access to 10+ additional ProTips, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Clorox’s fiscal third-quarter earnings report revealed a miss on both revenue and earnings per share, with an EPS of $1.45 falling short of analyst expectations. Organic sales declined by 2% year-over-year, contrary to projections of flat growth, due to slowing consumption and retailer inventory reductions. Despite these setbacks, Clorox’s gross margin increased to 44.6%, surpassing expectations. The company’s full-year 2025 EPS outlook remains unchanged, with an anticipated benefit from sales pullforward. Jefferies adjusted its price target for Clorox shares to $167, maintaining a Buy rating, while Wells Fargo (NYSE:WFC) reduced its price target to $142 and maintained an Equal Weight rating. JPMorgan also revised its price target to $144, maintaining a Neutral rating, citing concerns over consumer demand and retailer destocking. Additionally, Clorox announced the appointment of Gina Boswell, CEO of Bath & Body Works, to its board of directors, expanding the board to 12 members. These developments reflect ongoing challenges and strategic adjustments within the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.